Two Sigma Advisers
ITCI

Two Sigma Advisers’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Two Sigma Advisers’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-38,967
Closed -$5.14M – 2605
2025
Q1 		$5.14M Sell
38,967
-104,300
-73% -$13M 0.01% 779
2024
Q4 		$12M Buy
+143,267
New +$11.8M 0.03% 435
2022
Q1 		– Sell
-11,467
Closed -$600K – 2949
2021
Q4 		$600K Buy
+11,467
New +$482K ﹤0.01% 1829
2020
Q2 		– Sell
-12,467
Closed -$192K – 2623
2020
Q1 		$192K Sell
12,467
-10,500
-46% -$228K ﹤0.01% 2182
2019
Q4 		$788K Sell
22,967
-115,800
-83% -$1.39M ﹤0.01% 1676
2019
Q3 		$1.04M Sell
138,767
-26,200
-16% -$251K ﹤0.01% 1420
2019
Q2 		$2.14M Buy
164,967
+39,100
+31% +$501K 0.01% 1181
2019
Q1 		$1.53M Buy
125,867
+97,600
+345% +$1.25M ﹤0.01% 1335
2018
Q4 		$322K Buy
+28,267
New +$456K ﹤0.01% 1956

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Two Sigma Advisers's ITCI Position: Q2 2025 in Review

Two Sigma Advisers sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 38,967 shares — an estimated $5.14M sold.

Two Sigma Advisers first reported a position in ITCI in Q4 2018 and held it in 9 quarters. The position peaked at $12M in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Two Sigma Advisers reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 38,967 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $5.14M.
  • Two Sigma Advisers first reported a position in Intra-Cellular Therapies Inc. in Q4 2018 and held it in 9 quarters.
  • Two Sigma Advisers's Intra-Cellular Therapies Inc. position peaked at $12M in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Two Sigma Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.